Drug Trial Radar · NCT02737371
Multiple Ascending Oral Dose Study of F901318 in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: May 23, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Actual
Start
May 2016
Primary completion
May 22, 2017
Study completion May 22, 2017
Sponsor
- Lead sponsor
- F2G LtdIndustry
- Sponsor type
- Industry
- Collaborators
- SimbecRresearch Ltd.
- First posted
- Apr 13, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Double blind, placebo controlled, ascending multiple (10) oral dose, sequential group study. Twenty-four subjects will complete the study in 3 cohorts (Groups A to C), each group consisting of 8 subjects. Each cohort will consist of 4 male and 4 female subjects. Each subject will be dosed for 10 days and will be on study for approximately 7 weeks. Each subject will participate in one treatment cohort only, residing at the Clinical Research Unit (CRU) from Day -1 (the day before dosing) to Day 15 (120 hours post the last dose). The dose will range between 2 and 10 mg/kg daily, given as either a single daily dose or as two doses divided over the 24-hour dosing period. All subjects will return for a post-study visit 8 to 10 days after the last dose of study medication. Cohorts will be dosed at least at 3 weekly intervals. There will be a review of the safety and pharmacokinetic data of each cohort prior to each dose escalation.
Conditions
- Invasive Aspergillosis
Interventions
F901318 Dose level A oralDrug
Adverse events days 1-10
Placebo dose level A oralDrug
Placebo adverse events days 1-10
F901318 Dose level B oralDrug
F901318 adverse events days 1-10
Placebo dose level B oralDrug
Placebo adverse events days 1-10
F901318 Dose level C oralDrug
F901318 adverse events days 1-10
Placebo Dose level C oralDrug
Placebo adverse events days 1-10
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment-Emergent Adverse Events [Safety and TolerabilityTime frame: 10 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Simbec Research Ltd
Merthyr Tydfil, Glamorgan, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.